Chemotherapy-Free Management of Indolent Lymphoma

In this video by VJHemOnc – Video Journal of Hematological Oncology, Wolfgang Hiddemann, MD, PhD, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma.

Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.

Learn more about lymphoma here:

Leave a Comment

Your email address will not be published. Required fields are marked *